Table 2.
Pharmacological approaches currently under development against PCSK9.
| Approach | Name | Company | Ref. |
|---|---|---|---|
| mAb to LDLR binding domain of PCSK9 | REGN727 | Regeneron Pharmaceuticals Inc. | [131–134] |
| mAb to LDLR binding domain of PCSK9 | mAb1 | Amgen Inc. | [131] |
| mAb to LDLR binding domain of PCSK9 | AMG 145 | Amgen Inc. | [135] |
| mAb to LDLR binding domain of PCSK9 | J16 | Pfizer Inc. | [136] |
| Fab and IgG2 to catalytic domain | 1D05 | Merck Research Laboratories | [137] |
| Fab to C terminal domain | 1G08 | Merck Research Laboratories | [138] |
| mAb to LDLR binding domain of PCSK9 | IB20 | Merck Research Laboratories | [139] |
| Antisense oligonucleotide | ISIS 394814 | Isis Pharmaceuticals, Inc. | [140] |
| Antisense oligonucleotide | SPC5001 SPC4061 | Santaris Pharma A/S | [141, 142] |
| siRNA | PCS-A2/B2/C2 | Alnylam Pharmaceuticals | [143] |
| Vaccine | Merck Research Laboratories | [144] |